Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Mann

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Journal of Orthopaedic Surgery (Hong Kong)|November 13, 2018
Outcomes of expedited rotator cuff surgery in injured workers: Impact of pathology on readiness for return to workGargi Singh, Helen Mann, Helen Razmjou
Clinical Lung Cancer|February 4, 2016
Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1)Pasi A Jänne, Helen Mann, Dana Ghiorghiu
Pharmaceutical Statistics|April 3, 2014
Utility values in health technology assessments: a statistician's perspectiveCaroline Whately-Smith, Claire Watkins, Helen Mann, et al.
Health Economics Review|April 23, 2020
The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancerJoanne Gregory, Matthew Dyer, Christopher Hoyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2018
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 TrialChee Khoon Lee, Silvia Novello, Anna Rydén, et al.
Disability and Rehabilitation|March 17, 2007
Family carers of stroke survivors: needs, knowledge, satisfaction and competence in caringAnn Mackenzie, Lin Perry, Elizabeth Lockhart, et al.
BMC Cancer|June 11, 2015
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)Richard D Carvajal, Gary K Schwartz, Helen Mann, et al.
Clinical Lung Cancer|May 24, 2018
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical ResectionYi-Long Wu, Roy S Herbst, Helen Mann, et al.
Studies in Health Technology and Informatics|August 12, 2015
Data Science Solution to Event Prediction in Outsourced Clinical Trial ModelsDaniel Dalevi, Susan Lovick, Helen Mann, et al.
Cancer Epidemiology|April 7, 2019
Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US settingJason C Simeone, Beth L Nordstrom, Ketan Patel, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Journal of Orthopaedic Surgery (Hong Kong)|November 13, 2018
Outcomes of expedited rotator cuff surgery in injured workers: Impact of pathology on readiness for return to workGargi Singh, Helen Mann, Helen Razmjou
Clinical Lung Cancer|February 4, 2016
Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1)Pasi A Jänne, Helen Mann, Dana Ghiorghiu
Pharmaceutical Statistics|April 3, 2014
Utility values in health technology assessments: a statistician's perspectiveCaroline Whately-Smith, Claire Watkins, Helen Mann, et al.
Health Economics Review|April 23, 2020
The validation of published utility mapping algorithms: an example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancerJoanne Gregory, Matthew Dyer, Christopher Hoyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2018
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 TrialChee Khoon Lee, Silvia Novello, Anna Rydén, et al.
Disability and Rehabilitation|March 17, 2007
Family carers of stroke survivors: needs, knowledge, satisfaction and competence in caringAnn Mackenzie, Lin Perry, Elizabeth Lockhart, et al.
BMC Cancer|June 11, 2015
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)Richard D Carvajal, Gary K Schwartz, Helen Mann, et al.
Clinical Lung Cancer|May 24, 2018
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical ResectionYi-Long Wu, Roy S Herbst, Helen Mann, et al.
Studies in Health Technology and Informatics|August 12, 2015
Data Science Solution to Event Prediction in Outsourced Clinical Trial ModelsDaniel Dalevi, Susan Lovick, Helen Mann, et al.
Cancer Epidemiology|April 7, 2019
Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US settingJason C Simeone, Beth L Nordstrom, Ketan Patel, et al.
Pageof 6